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cal disease in Singapore and Hong Kong from a payer perspective. METHODS: A 
decision-analytic model was developed to estimate the impact of vaccination with 
PCV13 relative to PCV7 and to PCV10 on invasive pneumococcal disease (IPD), 
pneumonia, and otitis media. Model inputs include disease incidence, sequelae, and 
mortality; serotype coverage; immunogenicity; direct and indirect effects; and costs. 
Speciﬁc local data were obtained from regional surveillance and published literature. 
Where local data were unavailable, proxy data were derived from published US 
sources. Vaccine costs assumed price parity to the private market unit price for PCV7 
and were based on a four dose schedule. Costs and outcomes were discounted at 3%. 
RESULTS: Preliminary results demonstrated that PCV13 was dominant compared to 
PCV10 and compared to PCV7, both with and without indirect effects, in Singapore 
and in Hong Kong. The net cost savings per child vaccinated with PCV13 compared 
to PCV7 was S$7 in Singapore and HK$1352 in Hong Kong when including indirect 
effects. With direct effects only, the net cost savings per child vaccinated was S$1 and 
HK$4 in the respective countries. PCV13 direct effects would reduce IPD by 86% 
amongst vaccinated children in both regions. Results also indicated further reductions 
in pneumonia and otitis media burden with PCV13. CONCLUSIONS: These prelimi-
nary results suggest that pediatric national immunization programs with PCV13 in 
Singapore and in Hong Kong are expected to substantially decrease pneumococcal 
illness. In addition, the programs are expected to be cost-savings relative to PCV10 
and to PCV7.
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COST-EFFECTIVENESS OF THREE ANTIRETROVIRAL SCHEMES AFTER 
A FIRST VIROLOGICAL FAILURE IN PATIENTS WITH HIV/AIDS IN 
COLOMBIA
Cañón V1, Alandete JC2, Rosselli D3
1Hospital Universitario Mayor, Bogota, DC, Colombia, 2Janssen-Cilag, Bogota, Colombia, 
3Universidad Jorge Tadeo Lozano, Bogota, DC, Colombia
OBJECTIVES: Determine cost-effectiveness and cost-utility of three treatment schemes 
(based on lopinavir [LPV/r], darunavir [DRV/r] and atazanavir [ATZ/r]) used in 
patients with HIV/AIDS after a ﬁrst virological failure, in Colombia. METHODS: We 
designed a Markov model with 10 six-month cycles (5-year timeframe) based on 
efﬁcacy measures obtained from published clinical trials. We estimated local direct 
costs from a payer perspective using 2009 ofﬁcial rates for drugs and lab tests, and 
real costs for AIDS-related complications (exchange rate Col$1968 per US$, January 
2010). Utilities (in QALYs) were obtained from the Tufts CEA registry. Effectiveness 
was measured as further virological failures, need of “rescue therapy”, AIDS-related 
complications, and deaths per 1000 patients (estimated through Monte Carlo proba-
bilistic simulation). We applied a 5% discount rate for costs and QALYs. RESULTS: 
Average cost per patient was US$ 39,334 for DRV/r, US$ 41,825 for LPV/r and US$ 
49,135 for ATZ/r. Five-year mortality was 5.9% in the DRV/r group, 7.6% for LPV/r 
and 8.0% for ATZ/r; there were 235 AIDS-related complications in the DRV/r group, 
383 in the LPV/r group and 326 in ATZ/r. Rescue therapy was required in 85 occa-
sions in the DRV/r group, 273 in the LPV/r group and 198 in the ATZ/r group, while 
there were 700 virological failures per 1000 patients in the DRV/r group, 1070 in 
LPV/r and 1080 in ATZ/r. Average QALYs gained in the ﬁve-year period were: DRV/r 
3.92; LPV/r 3.81 and ATZ/r 3.84. Cost-utility and cost-effectiveness analysis show 
darunavir as the dominant alternative since the ﬁrst year compared to atazanavir, and 
since the fourth year compared to lopinavir. One way sensitivity analyses did not 
modify the results signiﬁcantly. CONCLUSIONS: In Colombia, initial treatment with 
darunavir in patients with a ﬁrst antiretroviral therapy failure is less costly than with 
lopinavir or atazanavir and is signiﬁcantly more effective.
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OBJECTIVES: To evaluate the cost-effectiveness of 2009 pandemic inﬂuenza 
A(H1N1) (pH1N1) vaccination in various age and risk groups in the United States. 
METHODS: A computer simulation model was developed to predict costs and health 
outcomes for a pH1N1 vaccination program using inactivated vaccine compared to 
no vaccination. The modeled target population included hypothetical cohorts of 
persons aged 6 months and older stratiﬁed by age and risk. Probabilities, costs and 
quality-of-life weights were derived from emerging primary data on pH1N1 infections 
in the US, published and unpublished data for seasonal and pH1N1 illnesses, supple-
mented by expert opinion. The analysis used a one-year time horizon for most end-
points but also included longer-term costs and consequences of long-term sequelae 
and deaths. A societal perspective was used. The main endpoint was the incremental 
cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensi-
tivity analyses were conducted to evaluate the robustness of results as parameters were 
varied over plausible ranges, including a scenario analysis to evaluate the effect of 
timing of vaccination assuming a hypothetical 16-week ﬂu season and normalized 
epidemic curve of illness. RESULTS: For vaccination initiated prior to the outbreak, 
pH1N1 vaccination was cost-saving for persons 6 months to 64 years with high risk 
conditions assuming a 15% overall attack rate. For those without high risk conditions, 
pH1N1 vaccination was not cost-saving but required a net investment; cost-effective-
ness ratios ranged from $8,000-$52,000/QALY depending on age and risk category. 
Results were sensitive to the number of vaccine doses needed, costs of vaccination, 
illness rates, and timing of vaccine delivery. Cost-effectiveness ratios increased sub-
stantially if vaccination were initiated after the 10th week of the start of a hypothetical 
16-week epidemic. CONCLUSIONS: Vaccination for pH1N1 for children and work-
ing-age adults is cost-effective compared to other preventive health interventions under 
a wide range of scenarios.
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OBJECTIVES: To evaluate the clinical-economic value of caspofungin therapy vs. 
standard and alternative treatments in patients with invasive candidiasis (IC) hospital-
ized in intensive care units (ICU). METHODS: The pharmacoeconomic analysis uti-
lized the cost-effectiveness analysis (CER). If the efﬁcacy and the cost of any of the 
studied regimens exceeded those of the other regimen, an incremental analysis was 
carried out (ICERs). A list of direct costs was compiled: clinical laboratory procedures 
carried out at invasive candidiasis diagnosis; antimycotic costs in the treatment of 
invasive candidiasis; antimycotic administration costs; costs of the diagnosis of adverse 
events following administration of an antimycotic. Efﬁcacy and safety data were based 
on additional analyses of a randomised, double blind, multinational trial of antimycot-
ics. To evaluate the degree of inaccuracy of the results, sensitivity analyses were 
performed RESULTS: It was established that the mode of starting treatment of IC 
amphotericin B and then caspofungin was both more effective and less expensive in 
comparison with the use of amphotericin B and then amphotericin B lipid complex. 
When we used caspofungin or amphotericin B lipid complex shares of expenses on 
antimycotices were 80–87%. Lower parameters are received at application ampho-
tericin B and ﬂuconazole, 46 % and 66 %, accordingly. The analysis of the alternative, 
whose efﬁciency of treatment of IC was equal in all groups, has shown, that the least 
expensive strategy was that where the starting therapy was amphotericin B. The 
unilateral analysis of sensitivity proves that the efﬁciency of expenses of the treatment 
of IC was more sensitive to a parameter of efﬁciency than to the change of the expenses 
connected with the price of medicines. CONCLUSIONS: In modern Russian condi-
tions, in view of a high level of resistance in vitro Candida spp. to ﬂuconazole and 
high toxicity of amphotericin B, the most expedient strategy is that starting what the 
application of caspofungin.
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OBJECTIVES: Candida species are a common cause of nosocomial bloodstream 
infection. Positive blood cultures or high clinical suspicion for candidemia prompt 
empiric antifungal therapy. Early species identiﬁcation allows earlier initiation of 
appropriate therapy or de-escalation to less expensive narrow spectrum therapy. Our 
institute used Candida PNA-FISH (Test A) to rapidly differentiate Candida albicans 
from non-albicans species. Two newer tests can differentiate among albicans, glabrata 
or others (Candida PNA-FISH dual probe, Test B) and among albicans/parapsilosis, 
tropicalis, glabrata/krusei or others (Candida PNA-FISH Trafﬁc Light, Test C). This 
study aimed to predict cost impacts if newer tests would have been used. METHODS: 
From a hospital administration perspective, a retrospective chart review of candidemic 
patients between January 2007 and May 2008 was conducted to obtain costs and 
utilization of antifungal medications and information on species identiﬁcation. Monte 
Carlo simulation models with certain assumptions and limitations were created to 
predict costs. Model inputs were determined based on real-world data. Only antifun-
gal medication costs, incorporating doses, frequencies and 2008 average wholesale 
prices, were considered. One-way and probabilistic sensitivity analyses (2,500 trials) 
were performed. RESULTS: There were 140 candidemic episodes in 132 patients. 
Candida species isolated included albicans (43%), glabrata (29%), parapsilosis (14%), 
tropicalis (6%), krusei (6%), and others. Compared to Test A, median potential cost 
savings per patient are $37 (95% CI $14-$104, Test B) and $51 (95% CI $22-$130, 
Test C). Minimal cost savings per patient are $24 (Test B) and $35 (Test C) at a 
probability of 80%. Two key variables were identiﬁed. Potential cost savings increase 
with increased empiric use of micafungin or decreased prevalence of Candida albicans. 
CONCLUSIONS: With sole consideration of antifungal medication costs, switching 
from Test A to Test C is likely to yield more cost savings than switching to Test B, 
but cost savings may not be substantial.
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OBJECTIVES: Complicated Skin and Skin Structure Infections (cSSSIs) are among 
the most common treated infections in the hospitals. Ceftobiprole has demonstrated 
efﬁcacy in treating cSSSIs in two non-inferiority trials, including those caused by 
methicillin-resistant Staphylococcus aureus (MRSA). It is currently under review 
